Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins [PDF]
Acta Cirúrgica Brasileira, 2005 PURPOSE: To evaluate the prognostic significance and correlation with staging and degree of cell differentiation of the tumoral expression of the proteins c-erbB-2 and E-cadherin, in patients with colorectal adenocarcinoma.
Jesus Eliane C. +5 more
doaj +3 more sources
Correlation of c-erbB-2, EGF and EGFR expression with postoperative survival of patients with advanced carcinoma of the stomach. [PDF]
Folia Histochemica et Cytobiologica, 2010 The c-erbB-2 (HER-2/neu), EGF and EGFR (erbB-1) proteins, members of the epidermal growth factor receptor family, play a role in cell growth by binding to cell membrane receptors.
Katarzyna Guzinska-Ustymowicz +2 more
doaj +3 more sources
Helicobacter pylori infection and expressions of EGF, EGFR and c-erbB-2 proteins in gastric carcinoma. [PDF]
Folia Histochemica et Cytobiologica, 2010 The family of epidermal growth factor (EGF, EGFR, c-erbB-2) plays a pivotal role in gastric cancer progression, invasion and metastasizing. Helicobacter pylori infection is known to contribute significantly to the formation and progression of gastric ...
Andrzej Kemona +3 more
doaj +3 more sources
Molecular markers (c-erbB-2, p53) in breast cancer. [PDF]
Folia Histochemica et Cytobiologica, 2009 The aim of our study was to evaluate the correlation between clinical characteristics, histopatologic features and c-erbB-2 as well as p53 expression in cancer tissues. Breast cancer tissue was obtained from 184 female subjects with primary breast cancer.
Piotr Zukrowski +5 more
doaj +3 more sources
c-Myb Repression of c- erbB-2 Transcription by Direct Binding to the c- erbB-2 Promoter [PDF]
Journal of Biological Chemistry, 1995 The c-myb proto-oncogene product (c-Myb) is a transcriptional activator that can bind to the specific DNA sequences. Although c-Myb also represses an artificial promoter containing the Myb binding sites, natural target genes transcriptionally repressed by c-Myb have not been identified.
G, Mizuguchi +7 more
openaire +2 more sources
Metastatic cancer cells from c-erbB-2 negative primary breast cancer maintain the original c-erbB-2/HIF1α phenotype [PDF]
Cancer Biology & Therapy, 2007 The expression of c-erbB-2 and HIF1alpha proteins is linked with an aggressive tumor phenotype and poor survival in breast cancer. In the present study we investigated whether this ominous effect is a result of c-erbB-2/HIF1alpha expressing clone appearance within the primary tumor, by examining the c-erbB-2/HIF1alpha expression status in the primary ...
Alexandra, Giatromanolaki +3 more
openaire +2 more sources
Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. [PDF]
, 2015 Squamous cell carcinoma of the cervix, highly prevalent in the developing world, is often metastatic and treatment resistant with no standard treatment protocol.
Bouvet, Michael +17 more
core +11 more sources
C-erbB-2 immunostaining: problems with interpretation. [PDF]
Journal of Clinical Pathology, 1994 AIMS--To assess the consistency and reproducibility of assessment of c-erbB-2 immunostaining, and to examine some of the problems relating to inter- and intraobserver variability in the documentation of positive staining; to profile the spectrum of cytoplasmic and membranous staining in a wide range of tumour types.
E W, Kay +4 more
openaire +2 more sources
Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy [PDF]
, 2002 Concentrations of soluble c-erbB-2 were determined in the sera of 64 patients with distant metastasis from advanced breast cancer receiving second-line hormone or chemotherapy in comparison to 35 breast cancer patients without detectable recurrent ...
Classen, S. +5 more
core +1 more source
C-erbB-2 in Serum of Patients Receiving Fractionated Paclitaxel Chemotherapy
The International Journal of Biological Markers, 1999 Humanized anti-c-erbB-2 antibodies (Herceptin®) in a weekly schedule are a new therapeutic option for the treatment of c-erbB-2-positive, advanced breast cancer (ABC).
D. Lüftner, S. Schnabel, K. Possinger
doaj +1 more source